Skip to main content
Retour
ZBIO logo

Zenas BioPharma, Inc.

Qualité des données : 100%
ZBIO
NASDAQ Healthcare Biotechnology
21,06 €
▲ 0,43 € (2,08%)
Cap. Boursière : 940,18M
Fourchette du Jour
19,81 € 21,68 €
Fourchette 52 Semaines
6,11 € 44,60 €
Volume
507 360
Moyenne 50J / 200J
22,89 € / 22,80 €
Clôture Précédente
20,63 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (627 pairs)

Métrique Action Médiane du Secteur
P/E -2,5 0,3
P/B 3,9 2,9
ROE % -136,2 3,7
Net Margin % -3777,4 3,8
Rev Growth 5Y % 10,0
D/E 0,3 0,2

Objectif de Cours des Analystes

Hold
37,00 € +75.7%
Low: 19,00 € High: 48,00 €
BPA Prévisionnel
-4,83 €
CA Est.
9,4 M

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 -0,93 €
-1,31 € – -0,36 €
510 M 1
FY2029 -2,68 €
-3,76 € – -1,04 €
310 M 1
FY2028 -3,84 €
-4,93 € – -2,04 €
160 M 5

Points Clés

Debt/Equity of 0,33 — conservative balance sheet
Negative free cash flow of -172,35M
Capital efficient — spends only 0,18% of revenue on capex

Croissance

Revenue Growth (5Y)
N/A
Revenue (1Y)100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-136,22%
ROIC-49,22%
Net Margin-3777,37%
Op. Margin-2113,85%

Sécurité

Debt / Equity
0,33
Current Ratio5,61
Interest Coverage0,00

Valorisation

P/E Ratio
-2,49
P/B Ratio3,88
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 100,00% Revenue Growth (3Y) -55,28%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 10,00M Net Income (TTM) -377,74M
ROE -136,22% ROA -98,46%
Gross Margin 99,44% Operating Margin -2113,85%
Net Margin -3777,37% Free Cash Flow (TTM) -172,35M
ROIC -49,22% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,33 Current Ratio 5,61
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -2,49 P/B Ratio 3,88
P/S Ratio 94,02 PEG Ratio -0,03
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 940,18M Enterprise Value 909,50M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Revenue 10,00M 5,00M 50,00M 0,0
Net Income -377,74M -156,99M -37,12M -119,28M
EPS (Diluted) -8,44 -3,76 -0,97 -3,11
Gross Profit 9,94M -134,14M 50,00M -61,69M
Operating Income -211,39M -163,89M -37,15M -76,20M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022
Total Assets 383,64M 369,97M 68,18M 74,58M
Total Liabilities 141,50M 57,51M 293,90M 266,87M
Shareholders' Equity 242,14M 312,46M -225,72M -192,29M
Total Debt 79,96M 1,00M 21,11M 1,53M
Cash & Equivalents 110,64M 319,74M 56,86M 67,21M
Current Assets 351,17M 355,92M 59,80M 68,44M
Current Liabilities 62,65M 57,29M 23,26M 25,97M